• Zhonghua yi xue za zhi · Dec 2009

    Comparative Study

    [Dose distributions of proton beam therapy for hepatocellular carcinoma: a comparative study of treatment planning with 3D-conformal radiation therapy or intensity-modulated radiation therapy].

    • Jia-min Li, Jin-ming Yu, Su-wen Liu, Qing Chen, Xiang-kui Mu, Qi-an Jiang, Mei-hong Zhao, and Jian-guang Zhang.
    • Shandong University School of Medicine, Jinan 250012, China. wjlijiamin@yahoo.com.cn
    • Zhonghua Yi Xue Za Zhi. 2009 Dec 8; 89 (45): 3201-6.

    ObjectiveA comparative dose distribution study has been undertaken between proton beam therapy (PBT), 3-dimensional conformal radiation therapy (3D-CRT) and intensity-modulated radiation therapy (IMRT) in the treatment of hepatocellular carcinoma (HCC), so as to assess the potential advantages of PBT.MethodsDose volume histograms (DVHs) were compared between PBT and 3D-CRT or IMRT planning at total dose of 66 Gy and 86 Gy in stage I patients (n = 10, diameter < or = 5 cm), 60 Gy and 72 Gy in stage IIA patients (n = 12, diameter = 5.1-10 cm).ResultsFor patients with stage I, the mean liver dose (Dmean), V10, V20 and V30 were 13.01 Gy, 51.89%, 36.13% and 21.24% for 3D-CRT, whereas they were 6.34 Gy, 30.23%, 17.86% and 10.66%, respectively, for PBT (P < 0.002). With dose escalation to 86 Gy, the Dmean, V10, V20 and V30 were 16.91 Gy, 67.51%, 46.84% and 27.61% for 3D-CRT, whereas they were 8.26 Gy, 39.31%, 23.22% and 13.86%, respectively, for PBT (P < 0.002). Compared with 3D-CRT with dose of 66 Gy, PBT reduced the Dmean, V10, V20 and V30 even with dose escalation to 86 Gy (P < 0.042). For patients with stage IIA, the Dmean, V10, V20 and V30 were 29.18 Gy, 72.25%, 58.17%, 44.01% and 24.92 Gy, 73.32%, 56.15%, 37.75% for 3D-CRT and IMRT, respectively, with dose of 60 Gy, whereas they were 16.28 Gy, 43.93%, 33.54% and 22.78%, respectively, for PBT (P < 0.002). With dose escalation to 72 Gy, the Dmean, V10, V20, V30 were 35.02 Gy, 86.70%, 69.80%, 52.81% and 29.90 Gy, 87.98%, 67.74% and 45.30% for 3D-CRT and IMRT, respectively, whereas they were 19.54 Gy, 52.72%, 40.25% and 27.34%, respectively, for PBT (P < 0.002). Compared with 3D-CRT and IMRT with total dose of 60 Gy, PBT reduced the Dmean, V10, V20 and V30 even with dose escalation to 72 Gy (P < 0.05). In all of the 22 cases, compared with 3D-CRT, PBT reduced the doses to the nonliver OARs (organs at risks) including spinal cord, right kidney and stomach (P < 0.002). Compared with IMRT, PBT also reduced the dose to the right kidney and stomach significantly, while no significant difference was found respect to the dose to spinal cord (P > 0.05).ConclusionCompared with 3D-CRT, PBT reduced the dose to the normal liver tissues and nonliver OARs significantly, even with 20 to 30.3 percent of dose escalation. Compared with IMRT, PBT reduced the dose to the normal liver tissues significantly, even with 20 to 30.3 percent of dose escalation. PBT reduced the dose to the right kidney and stomach significantly. No significant difference was observed respect to the dose to spinal cord.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…

What will the 'Medical Journal of You' look like?

Start your free 21 day trial now.

We guarantee your privacy. Your email address will not be shared.